首页 | 本学科首页   官方微博 | 高级检索  
     检索      


Total Syntheses and Biological Reassessment of Lactimidomycin,Isomigrastatin and Congener Glutarimide Antibiotics
Authors:Dr Kévin Micoine  Dipl‐Chem Peter Persich  Dr Josep Llaveria  My‐Hanh Lam  Dr Andreas Maderna  Dr Frank Loganzo  Prof Alois Fürstner
Institution:1. Max‐Planck‐Institut für Kohlenforschung, 45470 Mülheim/Ruhr (Germany), Fax: (+49)?208?306‐2994;2. Pfizer Oncology, 401 N. Middletown Road, Pearl River, NY, 10965 (USA);3. Pfizer Oncology Medicinal Chemistry, 445 Eastern Point Road, Groton, CT 06340 (USA)
Abstract:Lactimidomycin ( 1 ) was described in the literature as an exquisitely potent cell migration inhibitor. Encouraged by this claim, we developed a concise and scalable synthesis of this bipartite glutarimide‐macrolide antibiotic, which relies on the power of ring‐closing alkyne metathesis (RCAM) for the formation of the unusually strained 12‐membered head group. Subsequent deliberate digression from the successful path to 1 also brought the sister compound isomigrastatin ( 2 ) as well as a series of non‐natural analogues of these macrolides into reach. A careful biological re‐evaluation of this compound collection showed 1 and progeny to be potently cytotoxic against a panel of cancer cell lines, even after one day of compound exposure; therefore any potentially specific effects on tumor cell migration were indistinguishable from the acute effect of cell death. No significant cell migration inhibition was observed at sub‐toxic doses. Although these findings cannot be reconciled with some reports in the literature, they are in accord with the notion that lactimidomycin is primarily a ribosome‐binder able to effectively halt protein biosynthesis at the translation stage.
Keywords:cell migration inhibition  cytotoxicity  metathesis  natural products  total synthesis
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号